News 10.02.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, was informed by its partner Novartis that the company...
Events, Internal events
Event date: 18.03.2022
Webinar 1 is available now. New webinars get available every 2 weeks.
In today’s competitive environment, the gene to First In Human (FIH) journey is complicated and more challenging than ever.
Competitors are chasing the same indications as well as the finite funding available.
There is increased pressure to get the...
News 03.02.2022 Schlieren (Zurich), Switzerland, February 3rd, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Granules has been cleared by the U.S. Food and Drug Administration (FDA) for expanded indications in the spine, making it only the second-ever bone graft...
Events, External events
Event date: 16.02.2022
All you need to know to get the best results - Join our Sanger sequencing webinar
Date: 16.02.2022
Time: 02:00 – 03:15 pm CET
Sanger sequencing is one of the pillars of work in a molecular biology lab. Whether or not your time in the lab is limited due to current events, a...
News 20.01.2022 Schlieren (Zurich), Switzerland, 20, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the publication of first-in-human data from a Phase II trial of Fibrin-PTH (KUR-113) in open tibial shaft fractures in The Journal of Bone and Joint Surgery (JBJS), the...